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Abstract: Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein expressed in the
cytosol of normal prostate tissue and highly overexpressed on the membrane of prostate cancer, therefore
increasingly used to image prostate cancer. We report a case of a 65-year-old man with two focal PSMA-
positive areas on a Ga-PSMA-11 PET/MR, one corresponding to a prostate carcinoma (Gleason score 4 +
3) and another region without any evidence of malignancy, but with corresponding high PSMA-expression
on immunohistochemistry.
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FIGURE 1. A 65-year-old man with prostate adenocarcinoma (PSA: 7.8 ng/ml and Gleason Score: 4 + 3 = 7 on biopsy),
was referred for a 68Ga-PSMA-11 positron emission tomography/magnetic resonance imaging (68Ga-PSMA-11 PET/MR) for
staging before radical prostatectomy. On PET/MR two focal areas in the prostate gland had intense 68Ga-PSMA-11
accumulation. PET/MR fusion image (A) shows intense PSMA-activity in the lesion located in the left paramedian peripheral
zone, from base to apex (white arrow), with T2-weighted hypointense signal on the axial T2 weighted MR sequence (B) and
diffusion restriction on the axial diffusion weighted images (DWI, b = 1000) (C). On histopathology (D) the prostate
adenocarcinoma had a high PSMA-expression on immunohistochemistry (green margin). A second focal area with intense
PSMA-activity on fused axial PET/MR image (E), was localized in the left midglandular transition zone (yellow arrow) anteriorly
to the tumor in the peripheral zone (white arrow), without corresponding abnormality seen on axial T2 weighted MR sequence
(F), or DWI (G). On histopathology (H) no malignancy was detected, despite a prominent overexpression of PSMA on
immunohistochemistry (yellow arrow).
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FIGURE 2. To exclude other specific histological abnormalities such as urothelial metaplasia or sclerosing adenosis in the
PSMA-overexpressing area in the transition zone, further immunohistochemistry was performed. On histopathology, the
transition zone tissue on hematoxylin and eosin staining (HE) (A) did not show any sign of malignancy. On PSMA
immunohistochemistry, however, a high PSMA-expression was seen (yellow arrow), with cytoplasmic and membranous
expression (B). S-100 did not show an atypical expression pattern (C), excluding a sclerosing adenosis.1 (D) GATA-3 only
showed minimal focal expression, corroborating that there is no significant urothelial metaplasia.2 68Ga-PSMA is known
to be overexpressed in nonprostatic tumor neovasculature,3,4 in several malignancies,5–9 as well as in benign conditions
like inflammation, osteoblastic processes and benign tumors.10,11 These potential pitfalls should be carefully taken into
consideration to avoid misinterpretation of 68Ga-PSMA-11 PET whole body scans. In the prostate gland, however,
68Ga-PSMA-11 PET is still considered very specific for primary prostatic malignancy, without any false positive reports.
A potential pitfall of mild, physiological increased 68Ga-PSMA-11 accumulation on PET imaging in the central zone was
recently described.12 However, with the presented case, we show that also normal prostatic tissue in the transition zone can
present with focal PSMA overexpression on cell membrane, without any signs of malignant transformation, benign tumors,
other malignancy (urothelial cancer) or inflammatory changes. This unusual presentation of normal glandular prostatic tissue
has the potential to lead to false positive findings on 68Ga-PSMA-11 PET in patients referred for prostate cancer staging.
Therefore, in the setting of primary evaluation of prostate cancer not only careful investigation regarding the sensitivity and
detection rate is mandatory, but also the cautious evaluation of the specificity to improve the understanding and accurate
interpretation of physiological 68Ga-PSMA-11 accumulation in the prostate.
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